Search results :

Bivalirudin

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: B01AE06

Side effects

Options: Hide MedDRA Preferred Terms

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7
Back pain Back pain postmarketing, 2.8% - 43.9% x x x x x x x
Pain Pain 2.4% - 16.6% x x x x x x
Pelvic pain Pelvic pain 6.02% - 7.86% x x x x x
Insomnia Insomnia 1.4% - 6.57% x x x x x x
Anxiety Anxiety 5.88% - 6.51% x x x x x
Bradycardia Bradycardia postmarketing, 1.2% - 7.62% x x x x x x x
Hypertension Hypertension 1% - 6.25% x x x x x x
Dyspepsia Dyspepsia 4.63% - 5.16% x x x x x
Abdominal pain Abdominal pain 0.8% - 4.83% x x x x x x
Gastrointestinal pain Abdominal pain 0.8% - 4.83% x x x x x x
Nervousness Nervousness 4.04% - 4.72% x x x x x
Tension Nervousness 4.04% - 4.72% x x x x x
Urinary retention Urinary retention 4.12% - 4.56% x x x x x
Ecchymosis Ecchymosis postmarketing, 0.0001% - 6% x x
Haemorrhage Major bleed postmarketing, 0.001% - 9.25% x x x
Haemorrhage postmarketing, 0.0001% - 28% x x x x
Hemorrhage symptom x
Hypotension Hypotension postmarketing, 0.2% - 17.2% x x x x x x x
Haemoglobin Haemorrhage postmarketing, 0.0001% - 28% x x x x
Headache Headache postmarketing, 0.2% - 12.2% x x x x x x x
Body temperature increased Body temperature increased 0.5% - 5.02% x x x x x x
Nausea Nausea postmarketing, 0.1% - 16.1% x x x x x x x
Injection site pain Injection site pain postmarketing, 0.1% - 12.7% x x x x x x x
Chest pain Chest pain postmarketing, 2.3% - 3.7% x x x x
Haematoma Haematoma postmarketing, 0.0001% - 7.5% x x x
Atrial fibrillation Atrial fibrillation 1% - 1.1% x x
Vomiting Vomiting postmarketing, 0.1% - 7.86% x x x x x x x
Ventricular tachycardia Ventricular tachycardia postmarketing, 0.9% - 1% x x
Epistaxis Epistaxis postmarketing, 0.0012% - 1.9% x x x
Angina pectoris Angina pectoris postmarketing, 0.2% - 5.3% x x x x x x
Gingival bleeding Gingival bleeding postmarketing, 0.12% - 1.5% x x
Melaena Melaena 0.22% - 0.4% x x
Thrombocytopenia Thrombocytopenia postmarketing, 0.3% - 1.1% x x x x x x
Retroperitoneal haemorrhage Retroperitoneal haemorrhage postmarketing, 0.069% - 0.697% x x x x x x x
Haemoptysis Haemoptysis postmarketing, 0.0046% - 0.5% x x
Haemorrhage intracranial Haemorrhage intracranial postmarketing, 0.0463% - 1% x x x x x x x
Anaphylactic shock Anaphylactic shock postmarketing x x x x x x
Anaemia Anaemia postmarketing x x
Arteriovenous fistula Arteriovenous fistula postmarketing x
Cardiac tamponade Cardiac tamponade postmarketing x
Compartment syndrome Compartment syndrome postmarketing x
Connective tissue disorder Connective tissue disorder postmarketing x x
Contusion Contusion postmarketing x
Coronary artery thrombosis Coronary artery thrombosis postmarketing x
Dyspnoea Dyspnoea postmarketing x x
Dermatitis Rash postmarketing x x x
Rash Rash postmarketing x x x
Eye disorder Eye disorder postmarketing x
Eye haemorrhage Eye haemorrhage postmarketing x
Gastrointestinal disorder Gastrointestinal disorder postmarketing x x
Gastrointestinal haemorrhage Gastrointestinal haemorrhage postmarketing x
Cardiac disorder Cardiac disorder postmarketing x x
Haematemesis Haematemesis postmarketing x x x
Haematuria Haematuria postmarketing x x x
Frank hematuria x
Pericardial haemorrhage Pericardial haemorrhage postmarketing x x
Peritoneal haemorrhage Peritoneal haemorrhage postmarketing x
Hypersensitivity Hypersensitivity postmarketing x x x x x x
Immune system disorder Immune system disorder postmarketing x x
Mediastinal disorder Mediastinal disorder postmarketing x
Myocardial infarction Myocardial infarction postmarketing x
Acute coronary syndrome Myocardial infarction postmarketing x
Acute coronary syndrome x
Nervous system disorder Nervous system disorder postmarketing x x
Reperfusion injury Reperfusion injury postmarketing x
Shock Shock postmarketing x x
Syncope x x x x
Thrombosis Thrombosis postmarketing x
Urethral disorder Urinary tract disorder postmarketing x
Urinary tract disorder Urinary tract disorder postmarketing x
Urticaria Urticaria postmarketing x x x
Angiopathy Angiopathy postmarketing x x
Pulmonary haemorrhage Pulmonary haemorrhage postmarketing x
Injection site reaction Injection site reaction postmarketing x x
Haemoglobin decreased Haemoglobin decreased postmarketing x
Skin disorder Unspecified disorder of skin and subcutaneous tissue postmarketing x
Oesophageal haemorrhage Oesophageal haemorrhage postmarketing x
Groin pain Groin pain postmarketing x
Ear haemorrhage Ear haemorrhage postmarketing x
Retroperitoneal haematoma Retroperitoneal haematoma postmarketing x
Anal haemorrhage Anal haemorrhage postmarketing x
Pharyngeal haemorrhage Pharyngeal haemorrhage postmarketing x
International normalised ratio increased International normalised ratio increased postmarketing x
Puncture site reaction Puncture site reaction postmarketing x
Injection site discomfort Injection site discomfort postmarketing x
Vascular pseudoaneurysm Vascular pseudoaneurysm postmarketing x
Thrombosis in device Coronary stent thrombosis postmarketing x
Catheter thrombosis postmarketing x
Vessel puncture site haematoma Vessel puncture site haematoma postmarketing x
Atelectasis Atelectasis x
Pneumothorax Atelectasis x
Coagulopathy Clotting x x x
Infection Infection x x x x
Confusional state Confusional state x x x x
Feeling abnormal Confusional state x x x x
VIIth nerve paralysis Facial paralysis x x x x
Oliguria Oliguria x x x x
Petechiae Petechiae x
Pleural effusion Pleural effusion x
Post procedural haemorrhage Postoperative hemorrhage x
Pulmonary oedema Pulmonary oedema x x x x
Renal failure Renal failure x x x x
Dizziness Syncope x x x x
Syncope Syncope x x x x
Loss of consciousness Syncope x x x x
Ventricular fibrillation Ventricular fibrillation x x x x
Injection site haemorrhage Injection site haemorrhage x
Vascular anomaly Vascular anomaly x x x x x
Sepsis Sepsis x x x x
Increased tendency to bruise Increased tendency to bruise x
Electrocardiogram ST segment elevation Electrocardiogram ST segment elevation x
Surgery Surgical intervention x x
Drug interaction Drug interaction x
Cerebral ischaemia Cerebral ischaemia x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

BIVALIRUDIN / ANGIOMAX

Side effects:30
Source:FDA

BIVALIRUDIN

Side effects:37
Source:FDA Structured Product Label

BIVALIRUDIN

Side effects:37
Source:FDA Structured Product Label

BIVALIRUDIN / ANGIOMAX

Side effects:39
Source:FDA

BIVALIRUDIN / ANGIOMAX

Side effects:42
Source:Health Canada

bivalirudin / bivalirudin

Side effects:73
Source:EMA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label